Xeloda Alternatives Compared
Xeloda | Palbociclib | Ibrance |
|
---|
Xeloda (capecitabine) | Palbociclib | Ibrance (palbociclib) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Colorectal Cancer, Breast Cancer - Metastatic, Breast Cancer, Pancreatic Cancer, Stomach Cancer, Esophageal Carcinoma. Xeloda may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Liposarcoma, Breast Cancer - Male, Breast Cancer. palbociclib may also be used for purposes not listed in this medication guide. |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Related suggestions Breast Cancer
|
|||||||||||||||
More about Xeloda (capecitabine) | More about Palbociclib | More about Ibrance (palbociclib) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Xeloda has an average rating of 6.7 out of 10 from a total of 30 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 30% reported a negative effect. |
Palbociclib has an average rating of 6.8 out of 10 from a total of 96 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 29% reported a negative effect. |
Ibrance has an average rating of 6.7 out of 10 from a total of 81 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: Xeloda side effects in more detail. |
See also: palbociclib side effects in more detail. |
See also: Ibrance side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Xeloda prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ibrance prices |
||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||
|
N/A |
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
Ibrance |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
0.75 hours |
29 hours |
29 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 277 drugs are known to interact with Xeloda:
|
A total of 455 drugs are known to interact with palbociclib:
|
A total of 455 drugs are known to interact with Ibrance:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
April 30, 1998 |
N/A |
February 03, 2015 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.